Quel est le prix pour Scilex Holding Company (SCLX)

Le prix pour Scilex Holding Company (SCLX) est $5.61

Quelle est la capitalisation boursière pour Scilex Holding Company (SCLX)

La capitalisation boursière pour Scilex Holding Company (SCLX) est $47.65M

Scilex Holding Company (SCLX) Marge Opérationnelle

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Année	Marge opérationnelle	Changez
Pas assez de données pour les dates fournies.

Année

Marge opérationnelle

Changez

Pas assez de données pour les dates fournies.

Entreprise	Marge opérationnelle	Différence de Marge Opérationnelle	Pays
Eli Lilly and Company LLY.US	43.92%	-	US
Johnson & Johnson JNJ.US	26.81%	-	US
AbbVie Inc. ABBV.US	29.32%	-	US
Roche Holding AG RO.SW	26.59%	-	CH
Merck & Co., Inc. MRK.US	16.65%	-	US

Entreprise

Marge opérationnelle

Différence de Marge Opérationnelle

Pays